I kind of think Dr Jay got a lot accomplished since he took over.

-completed the Amerex case
-both clinical holds completely lifted
-started new trials
-further understanding of MOA with leronlimab in PDL1 and its synergy with check point inhibitors
-company is funded and moving as fast as possible while being accurate as possible
-SEC investigation completed and nothing further required of company
-private benefactors willing to fund 2 trials I believe

Also I’m sure some things I am forgetting.

Seems like we are ready to start heading for the open water now as he mentioned.

Merck is looking for new revenue due to Keytuda patent expiration soon.

I would think if leronlimab does exactly what they think it does with cold tumors, that some type of collaboration with Merck would be ideal for all involved.

I also would like things to move faster, but I do think they are advancing as fast as they can, while also being as thorough and accurate as they can.

“Fast is fine, accuracy is final”

Just my 2 cents but it’s probably only worth 1 cent